Author Archives: Becky Means

DPYD Safety Update: Reducing the Risk of Critical or Fatal Chemotherapy Side Effects

Posted by Becky Means on October 16, 2025 | Featured

Aranscia® solutions help oncologists comply with new FDA warning label requiring DPYD genetic testing in patients receiving select chemotherapies HOUSTON, Oct. 16, 2025 /PRNewswire/ — Oncologists and pharmacy experts are reacting to last week’s Food and Drug Administration warning that requires genetic testing … Read More

Tags: chemotherapy, DPYD, FDA, Oncology

PGx Biomarker Testing: Covered Soon for All Californians

Posted by Becky Means on March 7, 2024 | Featured

Good news for CA providers and residents! Starting July 1, 2024, Pharmacogenomic (PGx) biomarker testing will be a covered benefit for all Californians*, regardless of insurance provider. PGx testing is already a covered benefit for Medicare patients. Read the press … Read More

Tags: ACS CAN, American Cancer Society Cancer Action Network, biomarker, California, Medi-Cal, PGx, pharmacogenomics, SB 496, Senate, University of California